Project Grant W81XWH1110062

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $798,173 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) federal grant program to The Ohio State University (OSU) to develop novel multivalent mucosal vaccines for human noroviruses (HuNoVs). The project aims to generate live-vectored mucosal HuNoV vaccines using FDA-approved rotavirus (RotaTeq) and measles/mumps/rubella (MMR) vaccine platforms. The multivalent RV-NoV and MMR-NoV vaccines...

Grant Award Summary Children's Mercy Hospital received a $433,175 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective July 1, 2025 through June 30, 2027. The award supports the development of a mosaic messenger ribonucleic acid (mRNA) vaccine designed to prevent hand, foot, and mouth disease (HFMD) caused by human enterovirus A viruses. The research deliverables include the design...

Federal Grant Award Summary Cincinnati Children's Hospital Medical Center received a $458,250 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded September 4, 2025, with completion targeted for August 31, 2027. The award funds development of S-VP4E, a pseudovirus nanoparticle (PVNP) rotavirus vaccine designed for oral immunization. The vaccine candidate consists of a calicivirus...

Cooperative Agreement Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Boston Children's Hospital a $1.67 million Cooperative Agreement under the Allergy and Infectious Diseases Research program (CFDA 93.855) on September 25, 2025, with an ultimate completion date of July 31, 2030. This Phase 1 study focuses on developing and evaluating a novel messenger RNA (mRNA)-lipid nanoparticle (LNP) vaccine for SARS-CoV-2 that incorporates two innovative technologies:...

This $242,250 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID, CFDA 93.855 Allergy and Infectious Diseases Research) on April 25, 2025, supports research to develop a vaccine against cryptosporidiosis, a common diarrheal disease in sub-Saharan Africa and Asia. The research team from the University of Virginia, in collaboration with the AAHI institute, aims to design and evaluate the protective efficacy of a novel liposomal vaccine formulation...

Federal Project Grant Award Summary Immport Therapeutics Inc., doing business as Antigen Discovery Inc., received a $300,000 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to optimize immunogenicity of novel Cryptosporidium vaccine candidates. The award, obligated on August 12, 2025, with a completion date of July 31, 2027, funds the development and testing of recombinant...

Federal Grant Award Summary Viva Viral Vaccines, Inc. received a $299,968 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 25, 2025, with a completion date of August 31, 2026. The award supports development of a broad-spectrum, multivalent vaccine platform targeting influenza neuraminidase (NA), a conserved viral protein that provides broad protective immunity...

Federal Project Grant Award Summary The University of North Carolina at Chapel Hill received a $427,625 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded September 8, 2025, with a completion date of August 31, 2027. This award supports research aimed at advancing the development of tools to better understand humoral (antibody) responses to sapovirus (SAV) following natural...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $33,116,067 Cooperative Agreement to the University of California, Irvine (UCI) for the "Allergy and Infectious Diseases Research" program (CFDA 93.855). The award, titled "The UCI Vaccines for Pandemic Preparedness Center (VPPC)", aims to conduct basic and translational research to develop prototype vaccines against emerging viruses. The project will characterize and compare two universal,...

The National Cancer Institute (NCI) awarded a Project Grant (CFDA 93.395 - Cancer Treatment Research) to Ampedrna Biosciences LLC in the amount of $398,823 to develop a highly immunogenic mini-circular RNA (mcrRNA) therapeutic cancer vaccine for human papillomavirus (HPV)-related cancers. The goal is to create an off-the-shelf or personalized vaccine that can elicit robust and durable T cell responses to target HPV E6 and E7 antigens, which are known to drive HPV-induced cancers. The proposed...